Ocuphire Pharma Investor Updates

P 10 Presbyopia VEGA-1 Phase 2 Design Randomized, Double-Masked, Placebo-Controlled One-Week Trial VEGA-1 17 US sites 150 presbyopic patients 0.75% Nyxol 4 arms Placebo Randomization Clinical trial NCT#04675151 Visit 1 Baseline Baseline Baseline Baseline Screening Evening Dosing (3-4 doses) Nyxol Nyxol Placebo Placebo Visit 2 (3-6 Days Later) LDP Drop No Treatment LDP Drop No Treatment Treatment Arms Nyxol + LDP Nyxol Alone LDP Alone Placebo Alone Phase 2 Enrollment Completed Feb to May 2021 – 150 Subjects Reporting Topline Results as Guided by End of 2Q21 Primary: % of subjects with ≥ 3 lines of improvement in distance- corrected near visual acuity comparing Nyxol + LDP vs placebo alone at 1 hour Endpoints Secondary: ● ● % of subjects with ≥ 2 and 23 lines gained at time points from 30 min to 6 hours in photopic and mesopic lighting comparing Nyxol + LDP vs placebo, Nyxol alone, and LDP alone No loss of distance vision Pupil diameter at time points Safety and tolerability (redness) Ocuphire PHARMA

View entire presentation